Discovery of target for inhibiting fibrosis in inflammatory bowel disease
By investigating NOX4's role in UC using NOX4-deficient mice, the study reveals its contribution to fibrosis and oxidative stress, providing a target for treating UC and preventing fibrosis progression in ulcerative colitis.
Patent Information
- Application Number
- PCT/KR2024/005979
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-03
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for ulcerative colitis (UC) are ineffective and associated with side effects, and there is a need to identify new therapeutic targets to prevent fibrosis and colorectal cancer, which are exacerbated by excessive reactive oxygen species (ROS) production and oxidative stress.
The study focuses on NOX4, an oxidizing enzyme, and its role in fibrosis development in UC, using NOX4-deficient mice to investigate its contribution to intestinal fibrotic damage and the involvement of TGF-β signaling, with the aim of predicting and suppressing fibrosis progression.
The research demonstrates that NOX4 deletion leads to severe fibrosis and failure in recovery, increasing oxidative stress and activating TGF-β signaling, suggesting NOX4 as a target for regulating redox signaling to treat UC and potentially preventing fibrosis progression.
Smart Images

Figure KR2024005979_07112024_PF_FP_ABST
Abstract
Description
Discovery of Targets for Suppressing Fibrosis in Inflammatory Bowel Disease
[0001] The present invention relates to the discovery of a target for suppressing fibrosis in inflammatory bowel disease and the prediction of fibrosis progression in inflammatory bowel disease using the same.
[0002] Ulcerative colitis (UC) is a common form of inflammatory bowel disease (IBD) caused by long-term inflammatory damage and ulceration of the colonic mucosa. Persistent inflammation induced by commensal bacteria affects the intestinal epithelial barrier and is considered a major cause of UC development. Despite a rapid increase in the number of UC patients due to modernization and the rise of Western-style diets, current treatments are ineffective in most UC patients and are associated with adverse effects such as tissue dysfunction, fibrosing strictures, and malignant transformation. UC-associated carcinogenesis primarily stems from inflammation-mediated excessive production of reactive oxygen species (ROS) in damaged tissues. The resulting disruption of redox balance induces oxidative stress, resulting in genetic mutations and molecular damage to lipids, DNA, and proteins. This ultimately transforms colon cells, leading to colon cancer. Given the poor prognosis of UC-associated colon cancer, there is an urgent need to identify novel therapeutic targets.
[0003] Meanwhile, the NOX (NADPH oxidase) family, which is an oxidase of nicotinamide adenine dinucleotide phosphate (NADPH), is primarily responsible for generating ROS, which play a role in pathogen clearance, barrier function maintenance, and mucosal repair after injury in the gastrointestinal tract. Specifically, NOX1 and DUOX2 are abundantly expressed in the intestinal epithelium as major sources of ROS in the intestinal mucosa, and mutations in them are associated with the risk of adult IBD. NOX1 contributes to intestinal homeostasis by regulating mucus cell differentiation, migration, microbial defense, and mediating mucus repair after injury, while DUOX2 is activated by pathogen-derived uracil to generate DUOX-dependent ROS and eliminate gut microbes caused by intestinal infections. NOX4 acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species (ROS), which have different functions depending on the organ. NOX4 appears to be associated with the development of ureteral obstruction and pulmonary hypertension, inducing FLT3 (fms-like tyrosine kinase 3) signaling and cellular response to stimulation in the disease. Recent studies have revealed a role for NOX4 in modulating inflammation-mediated pathophysiology in the colon. NOX4 generates H2O2 and is primarily expressed in vascular smooth muscle cells, endothelial cells, and fibroblasts. We found that Nox4 transcripts are detected at low levels in normal colons, but NOX4 expression is upregulated in drug-resistant patients with fibrostenosis in UC or Crohn's disease (CD) and in a dextran sulfate sodium (DSS)-induced murine colitis model. Previously, NOX4 was not associated with the development of fibrotic features in mouse colitis models, and the detailed molecular mechanisms underlying fibrosis in UC have not been elucidated.
[0004] Based on this background, we hypothesized that NOX4 contributes to intestinal fibrosis damage in ulcerative colitis and that TGF-β signaling is required to induce fibrosis development. To test this hypothesis, we used NOX4-deficient mice (Nox4 - / - ) and investigated the effect of Nox4 on the response to intestinal damage. This study is expected to be of great use in predicting and suppressing the progression of fibrosis in inflammatory bowel disease.
[0005] We hypothesized that NOX4 contributes to intestinal fibrotic damage in ulcerative colitis and that TGF-β signaling is required to induce fibrosis development. To test this hypothesis, we used NOX4-deficient mice (Nox4) with DSS-induced colitis. - / - ) and investigated the effect of Nox4 on the response to intestinal damage.
[0006] Therefore, the purpose of the present invention is to elucidate the role of TGF-β signaling in contributing to the intestinal fibrosis damage of colitis and inducing the development of fibrosis in ulcerative colitis.
[0007] Another object of the present invention is to provide a composition for predicting whether fibrosis progresses in colitis.
[0008] Another object of the present invention is to provide a kit for predicting whether fibrosis progresses in colitis.
[0009] Another object of the present invention is to provide a method for predicting whether fibrosis progresses in colitis.
[0010] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating fibrosis in colitis.
[0011] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
[0012] Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and processes, are set forth to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or in conjunction with other known methods and configurations. In other instances, well-known processes and manufacturing techniques have not been described in specific detail so as not to unnecessarily obscure the present invention. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the appearances of “in one embodiment” or “an embodiment” in various places throughout this specification do not necessarily refer to the same embodiment of the present invention. Additionally, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
[0013] Unless otherwise specifically defined in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.
[0014] Throughout the specification, whenever a part is said to “include” a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise stated.
[0015] Our study provides evidence that Nox4 deficiency activates TGF-β signaling in the colon, leading to a transition to a moderate fibrotic phenotype and subsequent recruitment of Treg in a type 2 immune response. Consequently, Nox4 - / - Mice did not survive due to failure to recover, suffering from more severe mucosal damage, increased immune response, and more severe fibrosis due to DSS-induced colitis than WT mice. Previous studies have reported that Nox4 does not play a role in fibrosis in a murine colitis model, but Nox4 - / - In mice, increased Tgfbr1 expression was observed after 6 days of 2.5% DSS-induced colitis (Redox Biol 2020;37:101752). In this study, 2.5% DSS was administered for 14 days, which resulted in more severe damage to the colon. This demonstrates that the severity of tissue damage varies depending on the DSS concentration and duration of administration in the establishment of a DSS-induced murine colitis model.
[0016] Nox4 is considered to be closely related to tissue fibrosis, but its specific role in the progression of fibrosis has been controversial. Nox4-induced ROS appear to induce tissue fibrosis by promoting apoptosis and mesenchymal cell differentiation and activation. Nox4 has been reported to play a crucial role in the mouse lung, inducing alveolar cell death by myofibroblast activation and subsequent bleomycin-induced fibrosis, and attenuating CCl4-induced liver injury, hepatocyte apoptosis, and liver fibrosis (Nat Med 2009;15:1077-81.). Conversely, another study showed that Nox4 contributed to the prevention of renal fibrosis in rat kidneys with chronic kidney injury by inhibiting tubular cell death and oxidative stress (J Am Soc Nephrol 2012;23:1967-76.). In particular, Nox4 inhibits ROS production by reducing Hif1a expression and antioxidant molecules in the Keap1-Nrf pathway, suggesting that Nox4 may positively regulate antioxidant activity in the kidney.
[0017] Similarly, our study results showed that loss of Nox4 increased redox signaling with a consequent increase in ROS levels in mouse colon tissue. The increase in ROS due to Nox4 deletion in the mouse colon is similar to the previously reported role of Nox4 in the kidney in suppressing ROS and regulating downstream signaling. These results may be related to the fact that Nox4 suppresses ROS production in the colon and inhibits TGF-β signaling and its downstream fibrosis-related signals, as well as type 2 immune-related signals. Nox4 - / -Functional enrichment analysis of DEGs identified in the colon revealed that collagen-related signaling was upregulated, consistent with changes in collagen protein levels, and Treg cell lineage type 2 immunity was activated. These data suggest that increased ROS stimulates TGF-β-mediated immune responses, such as type 2 immunity for host defense, and induces Treg cells for immune tolerance, thereby activating immunosuppression.
[0018] The TGF-β signaling pathway is widely linked to tissue physiology, including collagen synthesis and Treg cell lineage determination. In this study, we found that loss of Nox4 alters the subset of T cells stimulated by persistently activated TGF-β in both normal and inflamed mouse colons. TGF-β signaling is regulated by naive CD4 + Foxp3 from T cells + Tregs and RORgT + We were able to directly induce the differentiation of Th17 cells. Nox4 under normal conditions (i.e., without DSS treatment). - / - The mouse is Foxp3 + Treg cell infiltration was significantly increased. Tregs are particularly involved in immune suppression against intestinal commensal bacteria. Nox4 - / - Foxp3 with increased ROS in the colon + Treg infiltration is mediated by TGF-β activation, proinflammatory cytokine (Tnf and Il1β) expression, and F4 / 80 + It induced macrophage infiltration. Therefore, the increase in Tregs was not only due to TGF-β activation but also Nox4 - / - It is considered to represent a defense mechanism that regulates the inflammatory immune response in the mouse colon.
[0019] After DSS-induced inflammation, Treg populations decreased and RORgT +Th17 cells were expanded. These results suggest that Nox4 regulates the Treg / Th17 balance during colitis. Further studies have shown that Th17 cells are more abundant in patients with active IBD and play a causal role in IBD-associated colon cancer. Colon cancer is typically densely infiltrated with proinflammatory cytokine-producing cells. Among tumor-infiltrating immune cells, T cells are transformed into a functional population that secretes large amounts of Th17-inducing cytokines (IL-17A, IL-12, IL-22), TNF-α, and IL-6. This population promotes colon tumor formation and survival through STAT3 / NF-κB activation. The results of the present study suggest that Th17 cells and associated cytokines are regulated by Nox4. - / - Suggests that it may improve the survival and growth of colon cancer in mice.
[0020] Increased oxidative stress has been linked to the development of chronic colitis. The NOX family has been proposed as a key driver of the progression of intestinal inflammation. Nox1 and Duox2 are expressed in the intestinal epithelium and are major sources of ROS in the gastrointestinal tract. Deficiency of these genes is associated with increased disease severity in colitis. Conditional deletion of Nox4 in fibroblasts and enterocytes results in a higher tumor burden, particularly in endothelial cells, and fibroblast-specific deletion of Nox4 results in faster tumor development than epithelial cell-specific deletion in Nox4 mice. In the present study, we found that Nox4 is expressed in non-epithelial cell populations, suggesting that Nox4 may determine the severity of colonic injury by regulating ROS-induced TGF-β signaling in colonic stromal cells.
[0021] In conclusion, we have demonstrated that genetic deletion of Nox4 leads to the progression of more severe fibrosing colitis and subsequent failure to recover. Loss of Nox4 increased oxidative stress in colonic tissue, which subsequently led to permanent activation of canonical TGF-β signaling. Furthermore, it affected the differentiation and proliferation of TGF-β-mediated T cell lineages (Treg and Th17 cells) and the progression of fibrosis in colitis. Our findings on the role of Nox4 in murine colitis suggest that modulating redox signaling may be an important target for the successful treatment of IBD patients.
[0022] According to one aspect of the present invention, the present invention comprises a preparation capable of measuring the expression level of Nox4 (NADPH Oxidase 4) protein, or a gene encoding the same, and capable of measuring the expression level of any one or more proteins selected from the group consisting of CD3e (Cluster of Differentiation 3 epsilon), Mucl1 (Mucin Like 1), Vegf (vascular endothelial growth factor), Ano5 (Anoctamin 5), Tnfrsf9 (TNF Receptor Superfamily Member 9), Itg2a (Integrin α2), Nlrp3 (NLR family pyrin domain containing 3), Tnfrsf4 (TNF Receptor Superfamily Member 4), Fabp7 (Fatty Acid Binding Protein 7), CD79b (Cluster of Differentiation 79B), Ptgs2 (Prostaglandin-endoperoxide synthase 2), and Caprin2 (Caprin Family Member 2), or a gene encoding the same. A composition for predicting the progression of fibrosis in colitis, which additionally includes a formulation, is provided.
[0023] According to the present invention, the colitis may be ulcerative colitis.
[0024] According to the present invention, the biological sample is selected from the group consisting of tissue, cell, cell extract, whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, It may be any one or more selected from the group consisting of synovial fluid, joint aspirate, organ secretions, and cerebrospinal fluid.
[0025] According to the present invention, the agent for measuring the expression level of the protein may include at least one selected from the group consisting of antibodies, oligopeptides, ligands, peptide nucleic acids (PNAs), and aptamers that specifically bind to the protein. In the present invention, the antibody refers to a substance that specifically binds to an antigen and causes an antigen-antibody reaction. For the purposes of the present invention, the antibody refers to an antibody that specifically binds to a protein that functions as the biomarker. The antibodies of the present invention include polyclonal antibodies, monoclonal antibodies, and recombinant antibodies. The antibodies can be easily produced using techniques well known in the art. For example, polyclonal antibodies can be produced by methods well known in the art, including a process of injecting an antigen of the biomarker protein into an animal and collecting blood from the animal to obtain serum containing the antibody. Such polyclonal antibodies can be produced from any animal, such as a goat, rabbit, sheep, monkey, horse, pig, cow, or dog. In addition, monoclonal antibodies can be produced using a hybridoma method widely known in the art (European Journal of Immunology, 6, 511-519.) or a phage antibody library technique (Mol. Biol., 222:58, 1-597, 1991). Antibodies produced by the above methods can be separated and purified using methods such as gel electrophoresis, dialysis, salt precipitation, ion exchange chromatography, and affinity chromatography. In addition, the antibody of the present invention includes not only a complete form having two full-length light chains and two full-length heavy chains, but also a functional fragment of an antibody molecule. A functional fragment of an antibody molecule means a fragment that has at least an antigen-binding function, and includes Fab, F(ab'), F(ab')2, and Fv.In the present invention, the PNA (Peptide Nucleic Acid) refers to an artificially synthesized polymer similar to DNA or RNA, and was first introduced in 1991 by Professors Nielsen, Egholm, Berg, and Buchardt of the University of Copenhagen, Denmark. While DNA has a phosphate-ribose sugar backbone, PNA has a repeated N-(2-aminoethyl)-glycine backbone linked by peptide bonds, which greatly increases binding affinity and stability to DNA or RNA, and is used in molecular biology, diagnostic analysis, and antisense therapy. PNA is disclosed in detail in the literature [Science 254 (5037): 1497-1500]. In the present invention, the aptamer is an oligonucleic acid or peptide molecule, and the general contents of the aptamer are disclosed in detail in the literature [Proc Natl Acad Sci USA. 95(24): 142727(1998)].
[0026] According to the present invention, the agent for measuring the expression level of the gene may include at least one selected from the group consisting of a primer, a probe, and an antisense nucleotide that specifically bind to the gene. In the present invention, the primer is a fragment that recognizes a target gene sequence, and includes a pair of forward and reverse primers, but is preferably a pair of primers that provide analysis results with specificity and sensitivity. When the nucleic acid sequence of the primer is a sequence that does not match a non-target sequence present in the sample, and thus amplifies only the target gene sequence containing the complementary primer binding site and does not cause non-specific amplification, high specificity can be provided. In the present invention, the probe refers to a substance that can specifically bind to a target substance to be detected in a sample, and refers to a substance that can specifically confirm the presence of the target substance in the sample through the binding. The type of the probe is not limited to a substance commonly used in the art, but may preferably be PNA (peptide nucleic acid), LNA (locked nucleic acid), peptide, polypeptide, protein, RNA, or DNA, and most preferably PNA. More specifically, the probe includes a biomaterial derived from or similar to a living organism or manufactured in vitro, and may be, for example, an enzyme, a protein, an antibody, a microorganism, an animal or plant cell and organ, a nerve cell, DNA, and RNA. DNA includes cDNA, genomic DNA, and oligonucleotides, RNA includes genomic RNA, mRNA, and oligonucleotides, and examples of proteins include antibodies, antigens, enzymes, and peptides. In the present invention, the LNA (Locked nucleic acids) refers to a nucleic acid analog containing a 2'-O, 4'-C methylene bridge (Gene Therapy (2006) 13, 496.502).LNA nucleosides contain the common nucleic acid bases of DNA and RNA and can form base pairs according to the Watson-Crick base pairing rules. However, due to the molecular 'locking' caused by the methylene bridge, LNAs cannot form an ideal shape in Watson-Crick bonds. When LNAs are included in DNA or RNA oligonucleotides, LNAs can pair more quickly with complementary nucleotide chains, thereby increasing the stability of the double helix. In the present invention, the antisense oligomer refers to an oligomer having a sequence of nucleotide bases and an intersubunit backbone that allows the antisense oligomer to hybridize with a target sequence in RNA through Watson-Crick base pairing, typically allowing the formation of an mRNA and RNA:oligomer heteroduplex within the target sequence. The oligomer may have exact sequence complementarity or approximate complementarity to the target sequence.
[0027] Since the biomarker protein according to the present invention or the information on the gene encoding the same is known, a person skilled in the art will be able to easily design a primer, probe, or antisense nucleotide that specifically binds to the gene encoding the protein based on this.
[0028] According to another aspect of the present invention, the present invention comprises a preparation capable of measuring the expression level of Nox4 (NADPH Oxidase 4) protein, or a gene encoding the same, and capable of measuring the expression level of any one or more proteins selected from the group consisting of CD3e (Cluster of Differentiation 3 epsilon), Mucl1 (Mucin Like 1), Vegf (vascular endothelial growth factor), Ano5 (Anoctamin 5), Tnfrsf9 (TNF Receptor Superfamily Member 9), Itg2a (Integrin α2), Nlrp3 (NLR family pyrin domain containing 3), Tnfrsf4 (TNF Receptor Superfamily Member 4), Fabp7 (Fatty Acid Binding Protein 7), CD79b (Cluster of Differentiation 79B), Ptgs2 (Prostaglandin-endoperoxide synthase 2), and Caprin2 (Caprin Family Member 2), or a gene encoding the same. A kit for predicting whether fibrosis progresses in colitis is provided, comprising a composition for predicting whether fibrosis progresses in colitis, which additionally includes a preparation.
[0029] According to the present invention, the kit may be an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or an MRM (Multiple reaction monitoring) kit. In addition, the kit of the present invention may further include one or more other component compositions, solutions, or devices suitable for the analysis method. For example, the kit of the present invention may further include essential elements necessary for performing a reverse transcription polymerase reaction. The reverse transcription polymerase reaction kit includes a primer pair specific for a gene encoding a marker protein. The primers are nucleotides having a sequence specific for the nucleic acid sequence of the gene, and may have a length of about 7 bp to 50 bp, more preferably about 10 bp to 30 bp. In addition, the kit may include a primer specific for the nucleic acid sequence of a control gene. Other reverse transcription polymerase reaction kits may include test tubes or other suitable containers, reaction buffers (with varying pH and magnesium concentrations), deoxynucleotides (dNTPs), enzymes such as Taq polymerase and reverse transcriptase, DNase, RNase inhibitor DEPC-water, sterile water, etc. In addition, the kit of the present invention may include essential elements necessary for performing a DNA chip. The DNA chip kit may include a substrate to which cDNA or oligonucleotides corresponding to a gene or a fragment thereof are attached, and reagents, agents, enzymes, etc. for producing a fluorescently labeled probe. In addition, the substrate may include cDNA or oligonucleotides corresponding to a control gene or a fragment thereof. In addition, the kit of the present invention may include essential elements necessary for performing an ELISA. The ELISA kit includes an antibody specific for the protein.Antibodies are antibodies that have high specificity and affinity for a marker protein and little cross-reactivity with other proteins. They can be monoclonal, polyclonal, or recombinant. ELISA kits may also include antibodies specific for a control protein. ELISA kits may also include reagents capable of detecting bound antibodies, such as labeled secondary antibodies, chromophores, enzymes (e.g., conjugated to antibodies), and their substrates or other substances capable of binding to antibodies.
[0030] According to another aspect of the present invention, the present invention provides a method for identifying a subject having colitis, comprising the steps of: (a) confirming an increase in the expression of Nox4 (NADPH Oxidase 4) protein, or a gene encoding the same, in a biological sample isolated from the subject; And, (b) a step of confirming an increase or decrease in the expression of at least one protein selected from the group consisting of CD3e (Cluster of Differentiation 3 epsilon), Mucl1 (Mucin Like 1), Vegf (vascular endothelial growth factor), Ano5 (Anoctamin 5), Tnfrsf9 (TNF Receptor Superfamily Member 9), Itg2a (Integrin α2), Nlrp3 (NLR family pyrin domain containing 3), Tnfrsf4 (TNF Receptor Superfamily Member 4), Fabp7 (Fatty Acid Binding Protein 7), CD79b (Cluster of Differentiation 79B), Ptgs2 (Prostaglandin-endoperoxide synthase 2), and Caprin2 (Caprin Family Member 2), or a gene encoding the same; is provided.
[0031] According to the present invention, the colitis may be ulcerative colitis.
[0032] According to the present invention, the biological sample is selected from the group consisting of tissue, cell, cell extract, whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, It may be any one or more selected from the group consisting of synovial fluid, joint aspirate, organ secretions, and cerebrospinal fluid.
[0033] According to the present invention, the method is a method for predicting that there is a high possibility that fibrosis will progress in colitis when the expression of any one or more proteins selected from the group consisting of CD3e, Mucl1, Vegf, Ano5, Tnfrsf9, Itg2a, and Nlrp3, or a gene encoding the same, is increased.
[0034] According to the present invention, the method is a method for predicting that there is a high possibility that fibrosis will progress in the colitis when the expression of any one or more proteins selected from the group consisting of Tnfrsf4, Fabp47, CD79b, Ptgs2, and Caprin2, or a gene encoding the same, is reduced.
[0035] At this time, the increase or decrease in expression of the protein or gene may be more than twice that of the normal control group.
[0036] According to the present invention, the method is a method in which an increase in the expression of the Nox4 (NADPH Oxidase 4) protein or a gene encoding the same is regulated by TGF-β (Transforming growth factor-beta).
[0037] According to the present invention, the method comprises (c) F4 / 80 + M1 macrophages, CD127 + Lymphocytes, regulatory T cells, or RORγT + It may additionally include a step of confirming an increase in Th17 cells (T helper 17 cells). At this time, the F4 / 80 + M1 macrophages, CD127 + Lymphocytes, regulatory T cells, or RORγT + This is a method for predicting that fibrosis is likely to progress in the above colitis when Th17 cells (T helper 17 cells) increase compared to the normal control group.
[0038] Also according to the present invention, the method comprises (c) CD163 + A step of confirming the reduction of M2 macrophages may be additionally included. At this time, the CD163 + This is a method for predicting that fibrosis is likely to progress in the above colitis when M2 macrophages are reduced compared to the normal control group.
[0039] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating fibrosis in colitis, comprising an inhibitor of expression of Nox4 (NADPH Oxidase 4) protein or a gene encoding the same, and further comprising an inhibitor of expression of at least one protein selected from the group consisting of CD3e (Cluster of Differentiation 3 epsilon), Mucl1 (Mucin Like 1), Vegf (vascular endothelial growth factor), Ano5 (Anoctamin 5), Tnfrsf9 (TNF Receptor Superfamily Member 9), Itg2a (Integrin α2), and Nlrp3 (NLR family pyrin domain containing 3), or a gene encoding the same.
[0040] According to the present invention, the colitis may be ulcerative colitis.
[0041] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating fibrosis in colitis, which comprises an inhibitor of expression of Nox4 (NADPH Oxidase 4) protein or a gene encoding the same, and further comprises an activator of expression of at least one protein selected from the group consisting of Tnfrsf4 (TNF Receptor Superfamily Member 4), Fabp7 (Fatty Acid Binding Protein 7), CD79b (Cluster of Differentiation 79B), Ptgs2 (Prostaglandin-endoperoxide synthase 2), and Caprin2 (Caprin Family Member 2), or a gene encoding the same.
[0042] According to the present invention, the colitis may be ulcerative colitis.
[0043] In the pharmaceutical compositions of the present invention, the term prevention means suppressing the occurrence of a disease or condition in a subject who has not been diagnosed as having the disease or condition but is susceptible to such disease or condition.
[0044] In the pharmaceutical compositions of the present invention, the term "treatment" refers to any action that improves symptoms caused by the target disease or benefits the individual by using the active ingredient of the present invention, and refers to an attempt to obtain useful or desirable results, including clinical results. Useful or desirable clinical results may include, but are not necessarily limited to, alleviation or improvement of one or more symptoms or conditions, reduction of the extent of the disease, stabilization of the disease state, inhibition of disease occurrence, inhibition of disease spread, delay or slowing of disease progression, delay or slowing of disease onset, improvement or alleviation of the disease state, and reduction (partial or complete). In addition, "treatment" may mean prolonging the survival of a patient beyond what would be expected in the absence of treatment. In addition, "treatment" may mean inhibition of disease progression, temporary slowing of disease progression, and more preferably relates to permanently stopping disease progression. As understood by those skilled in the art, if a treatment, while improving a particular disease state, produces adverse effects in the treated patient, i.e., effects that outweigh any benefits achieved by the treatment, the results may be unbeneficial or undesirable.
[0045] Accordingly, the composition of the present invention can be used on its own as a composition for treating these diseases, or it can be administered in combination with other anticancer agents to serve as an adjuvant treatment for these diseases. Accordingly, the terms "treatment" or "therapeutic agent" herein encompass the meanings of "adjuvant treatment" or "adjuvant treatment agent."
[0046] In the pharmaceutical compositions of the present invention, the expression inhibitor of any one or more proteins selected from the group consisting of Nox4, CD3e, Mucl1, Vegf, Ano5, Tnfrsf9, Itg2a, and Nlrp3 may include an antibody specific for the target protein, or an antigen-binding fragment thereof. Inhibition of protein activity here means inhibiting the activity of the target protein with an antibody specific for the protein, or an antigen-binding fragment thereof. The antibody is a term known in the art and refers to a specific protein molecule directed against an antigenic site. Such antibodies can be produced by cloning each gene into an expression vector according to a conventional method to obtain a protein encoded by the marker gene, and then producing the obtained protein by a conventional method. This also includes a partial peptide that can be produced from the protein, and the partial peptide of the present invention includes at least 7 amino acids, preferably 9 amino acids, and more preferably 12 or more amino acids. The form of the antibody of the present invention is not particularly limited, and a polyclonal antibody, a monoclonal antibody, or a part thereof having antigen binding properties are also included in the antibody of the present invention, and all immunoglobulin antibodies are included. Furthermore, the antibody of the present invention also includes special antibodies such as humanized antibodies. The antibody of the present invention includes not only a complete form having two full-length light chains and two full-length heavy chains, but also a functional fragment of an antibody molecule. A functional fragment of an antibody molecule means a fragment that has at least an antigen binding function, and includes Fab, F(ab'), F(ab') 2, and Fv.Alternatively, the expression inhibitor of any one or more genes selected from the group consisting of Nox4, CD3e, Mucl1, Vegf, Ano5, Tnfrsf9, Itg2a, and Nlrp3 may be any one or more selected from the group consisting of antisense oligonucleotides, siRNAs, shRNAs, and microRNAs specific for the target gene. The antisense oligonucleotides are short synthetic DNA strands (or DNA analogs) that are antisense (or complementary) to a specific DNA or RNA target, and are used to achieve gene-specific inhibition both in vivo and in vitro. Antisense oligonucleotides have been proposed to block the expression of a protein encoded by a DNA or RNA target by binding to the target and stopping expression at the stage of transcription, translation, or splicing. Antisense oligonucleotides have also been successfully used in cell culture and animal models of disease. Other modifications of antisense oligonucleotides to make the oligonucleotides more stable and resistant to degradation are known and understood by those skilled in the art. The antisense oligonucleotides used herein include double-stranded or single-stranded DNA, double-stranded or single-stranded RNA, DNA / RNA hybrids, DNA and RNA analogs, and oligonucleotides with base, sugar, or backbone modifications. The oligonucleotides are modified by methods known in the art to increase stability and resistance to nuclease degradation. These modifications include, but are not limited to, modifications of the oligonucleotide backbone, modifications of the sugar moiety, or modifications of the bases, all of which are known in the art.The above siRNA (small interfering RNA) is a nucleic acid molecule that can mediate RNA interference or gene silencing, and is used as an efficient gene knockdown method or gene therapy method because it can suppress the expression of a target gene. When the siRNA molecule is used in the present invention, it can have a double-stranded structure in which the sense strand and the antisense strand are positioned opposite each other, or a single-stranded structure with self-complementary sense and antisense strands. The double-stranded RNA portion of siRNA is not limited to completely pairing with each other, and may include a portion that does not pair due to a mismatch (corresponding bases are not complementary), a bulge (lack of corresponding bases in one strand), etc. The siRNA terminal structure can be either a blunt end or a cohesive end, as long as it can suppress the expression of the target gene through the RNA interference (RNAi) effect. The sticky end structure can be either a 3'-end overhang structure or a 5'-end overhang structure. The siRNA molecule is not limited thereto, but may have a total length of 15 to 30 bases, preferably 19 to 21 bases. The shRNA (short hairpin RNA) is a single-stranded RNA having a length of 45 to 70 nucleotides. After synthesizing an oligo DNA that connects a 3-10 base linker between the sense strand of the target gene siRNA base sequence and the complementary antisense strand, cloning it into a plasmid vector or inserting the shRNA into a retrovirus such as a lentivirus or adenovirus and expressing it, a looped hairpin structure shRNA is created, which is converted into siRNA by dicer in the cell and exhibits an RNAi effect.The above microRNA regulates various biological processes such as development, differentiation, proliferation, preservation, and apoptosis. MicroRNA generally regulates the expression of a gene encoding a target mRNA by destabilizing the target mRNA or interfering with its translation. Regulatory sequences useful for the expression construct / vector containing the antisense oligonucleotide, siRNA, shRNA, or microRNA (e.g., constitutive promoter, inducible promoter, tissue-specific promoter, or a combination thereof) can also be appropriately selected from those known in the art, and the expression inhibitor of the gene can be any substance that suppresses the expression of the gene in addition to the antisense oligonucleotide, siRNA, shRNA, or microRNA.
[0047] The pharmaceutical compositions of the present invention are not limited thereto, but may be formulated and used in the form of oral dosage forms such as powders, granules, capsules, tablets, and aqueous suspensions, as well as in the form of topical preparations, suppositories, and sterile injectable solutions, according to conventional methods. The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, coloring agents, and fragrances for oral administration, and may include buffers, preservatives, analgesics, solubilizers, isotonic agents, and stabilizers for injections. For topical administration, bases, excipients, lubricants, and preservatives for topical administration may be used. The formulations of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with the pharmaceutically acceptable carriers described above. For example, for oral administration, it can be manufactured in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injections, it can be manufactured in the form of unit dose ampoules or multiple doses. In addition, it can be formulated as a solution, suspension, tablet, capsule, sustained-release preparation, etc. Meanwhile, examples of carriers, excipients, and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, or mineral oil. Additionally, fillers, anti-coagulants, lubricants, humectants, fragrances, emulsifiers, preservatives, etc. may be included.Here, the term administration in this specification means directly administering a therapeutically effective amount of the composition of the present invention to a subject so that the same amount is formed in the body of the subject, and includes introducing the composition of the present invention to a patient by any appropriate method, and the route of administration of the composition of the present invention may be administered through any general route as long as it can reach the target tissue. Oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, rectal administration, intracavitary administration, intraperitoneal administration, and intrathecal administration may be performed, but is not limited thereto. In the present invention, the effective amount may be adjusted according to various factors including the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, body weight, general health condition, sex, and diet, administration time, administration route, and secretion rate of the composition, treatment period, and concurrently used drugs. For adults, the therapeutic pharmaceutical composition can be administered into the body in an amount of 50 ml to 500 ml at a time, and in the case of a compound, it can be administered in a dose of 0.1 ng / kg to 10 mg / kg, and in the case of a monoclonal antibody, it can be administered in a dose of 0.1 ng / kg to 10 mg / kg. The dosing interval can be 1 to 12 times a day, and in the case of administering 12 times a day, it can be administered once every 2 hours. In addition, the pharmaceutical composition of the present invention can be administered alone or together with other treatments known in the art, such as chemotherapy, radiation, and surgery, for the treatment of the target cancer. In addition, the pharmaceutical composition of the present invention can be administered in combination with other treatments designed to enhance the immune response, such as adjuvants or cytokines (or nucleic acids encoding cytokines) known in the art. Other standard delivery methods, such as biolistic delivery or ex vivo treatment, can also be used.In ex vivo treatment, for example, antigen-presenting cells (APCs), dendritic cells, peripheral blood mononuclear cells, or bone marrow cells can be obtained from a patient or a suitable donor, activated in vitro with the pharmaceutical composition, and then administered to the patient. In addition, the term therapeutically effective amount in this case means the content of the composition containing a pharmacological ingredient in the composition sufficient to provide a therapeutic or preventive effect to a subject to whom the pharmaceutical composition of the present invention is to be administered, and includes a preventive effective amount.
[0048] In this study, the researchers demonstrated that genetic deletion of Nox4 leads to the progression of more severe fibrosing colitis and subsequent failure to recover. Loss of Nox4 increased oxidative stress in colonic tissue, which subsequently permanently activated canonical TGF-β signaling. Furthermore, it affected the differentiation and proliferation of TGF-β-mediated T cell lineages (Treg and Th17 cells) and the progression of fibrosis in colitis. Therefore, the present invention is expected to be of significant use in predicting and suppressing the progression of fibrosis in inflammatory bowel disease.
[0049] Fig. 1 is Nox4 - / -Figures 1a and 1b illustrate the generation of mice with Nox2 or Nox4 deletion using CRISPR / Cas9 technology. The generated heterozygous and homozygous mice were genotyped by PCR using specific Nox2 or Nox4 deletion sites. Figure 1c (left) shows the results of ISH for mNox4 in untreated and 2.5% DSS-treated colon sections, and Figure 1c (right) shows the results of immunohistochemistry for Nox2 in untreated and 2.5% DSS-treated colon sections. Figure 1d shows the results of Sirius-red staining, showing areas of fibrosis in red. The graph shows numerical measurements of the fibrotic area using Image J. Figures 1e and 1f show the levels of intracellular reactive oxygen species (ROS) assessed using DCFH-DA staining in untreated and DSS-treated groups. Data are presented as mean ± SD, and significance is *P < 0.5, **P < 0.01 compared to wild type (WT).
[0050] Figure 2 shows that Nox4 has a protective function in experimental colitis induced by dextran sulfate sodium (DSS). Figure 2a shows the experimental plan for establishing a DSS-induced murine colitis model. Figure 2b shows the daily measured DSS-induced colitis in wild-type (WT) and Nox4 mice. - / - Weight loss in mice (n=6) is shown. Figure 2c shows the weight loss in WT or Nox4 mice with DSS-induced colitis. - / - Survival results up to 14 days are shown in mice (n=6). Figure 2d shows the survival results of WT and Nox4 mice with DSS-induced colitis sacrificed on day 14. - / - The results of macroscopic observation of the colon of mice are shown. Colon length was assessed after euthanasia of the mice. Figure 2e shows the results of DSS-induced colitis in WT and Nox4 - / -Representative hematoxylin and eosin staining images of colon tissues from mice are shown. Figure 2f shows the results of DSS-induced colitis in WT and Nox4 - / - Colitis scores for pathological evaluation of mice are presented. Inflammation severity was scored as none (0), mucosal inflammation (1), submucosal inflammation (2), and transmural inflammation (3) based on the degree of inflammation. Figure 2g shows the disease activity index, which consists of daily measured body weight loss, stool consistency, and rectal bleeding assessment. Data are expressed as mean ± SD, and significance is *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 compared to the wild type (WT).
[0051] Figure 3 shows that Nox4 is involved in intestinal fibrosis and immune-mediated tissue regeneration. Figure 3a shows wild-type (WT) and Nox4 treated with dextran sulfate sodium (DSS). - / - Immunohistochemical (IHC) staining results for F4 / 80 (top), representing M1 macrophages, CD164 (middle), representing M2 macrophages, and CD127 (bottom), representing lymphocytes, in mouse colon sections. Figure 3b shows the immunohistochemical (IHC) staining results for Ki-67, representing proliferating cells. IHC quantification of the 2.5% DSS treatment group was evaluated using ImageJ software, and the results are displayed as a bar graph on the right side of the image. Gray bars represent the WT group (n=3), and red bars represent Nox4. - / - Group (n=3). Figure 3c shows the results of Sirius Red staining (top), which shows fibrotic areas in red, and immunolabeling using Tenascin-C antibody (bottom), which indicates fibrosis in colonic tissue. Each positive staining area was measured by ImageJ, and the results are displayed as a bar graph next to each image. Gray bars represent the WT group (n=3), and red bars represent the Nox4 group. - / -Group (n=3). Figure 3d shows the RT-qPCR results of the inflammation-related genes Tnf and Il1b, and Figure 3e shows the RT-qPCR results of the fibrosis-related genes Col1a1, Col3a1, and Tnc. Data are expressed as mean±SD, and significance is *P<0.05, **P<0.01, ***P<0.005, ****P<0.001 compared to the wild type (WT).
[0052] Figure 4 shows wild type (WT) and Nox4 - / - Figure 4a shows the results of immune cell infiltration in the mouse colon. Figure 4a shows the results of immunohistochemical (IHC) staining for F4 / 80 (top), representing M1 macrophages, CD164 (middle), representing M2 macrophages, and CD127 (bottom), representing lymphocytes. Figure 4b shows the results of immunohistochemical (IHC) staining for Ki-67, representing proliferating cells. IHC quantification of the non-DSS-treated group was evaluated using ImageJ software, and the results are displayed as a bar graph on the right side of the image. Gray bars represent the WT group (n=3), and red bars represent Nox4. - / - Group (n=3). Figure 4c shows the results of Sirius Red staining (top), which shows fibrotic areas in red, and immunolabeling using Tenascin-C antibody (bottom), which indicates fibrosis in colonic tissue. Each positive staining area was measured by ImageJ, and the results are displayed as a bar graph next to each image. Gray bars represent the WT group (n=3), and red bars represent the Nox4 group. - / - Group (n=3). Data are expressed as mean±SD, and significance is *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 compared to wild type (WT).
[0053] Figure 5 shows that loss of Nox4 leads to collagen synthesis and infiltration of regulatory T cell (Treg) lineages. Figure 5a shows wild-type (WT) (n=3) and Nox4 treated with 2.5% DSS or vehicle.- / - (n=3) Plan for bulk RNA sequencing of distal colon tissue from mouse groups. Figure 5b shows DSS-untreated or -treated WT and Nox4 - / - Two-dimensional and three-dimensional principal component analysis (PCA) plots of the molecular signatures of the colon tissues of the group. Figure 5c shows the Nox4 expression compared to the WT group. - / - Volcano plot of genes that are downregulated (blue) or upregulated (red) with a difference in expression level of more than twofold. Figure 5d shows Nox4 - / - Gene ontology (GO) and biological process (BP) analysis results of upregulated DEGs in mice. Figure 5e shows Nox4 - / - This is the result of KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis of DEGs. The top 14 pathways are identified, and the colors indicate statistical significance. Figure 5f shows the results of WT and Nox4 - / - T cell subpopulations evaluated by CIBERSORT based on DEG. Figure 5g shows the WT and Nox4 - / - Results of CIBERSORT analysis of colon tissue. The relative proportions of 11 different immune cell types were isolated from RNA sequencing data using CIBERSORT. Figure 5h shows the results of WT or Nox4 - / - Flow cytometric analysis of distal colon tissue isolated from mice revealed that CD4 + Foxp3 + Relative number of live cells connected to T cells (left, histogram) and CD4 + Foxp3 + The number of T cells (right, bar graph) is shown. Figure 5i shows WT or Nox4 - / - The results of gene set enrichment analysis based on DEG. The TGF-β gene set includes Nox4 - / - Genes upregulated in the mouse colon are abundant.
[0054] Figure 6 shows that Nox4 inhibits the activation of TGF-β signaling in vivo. Figure 6a shows the general TGF-β signaling pathway system. Figure 6b shows the wild-type (WT) or Nox4 - / - RT-qPCR analysis of the expression of TGF-β-regulated genes in mouse colon tissue (the mice used here are different from those used for RNA sequencing (n=3)). In the graph, black dots represent WT mice not treated with DSS, and red dots represent Nox4. - / - Figure 6c shows the expression of WT (black) or Nox4 as measured by enzyme-linked immunosorbent assay. - / - (Red) indicates the level of active TGF-β in colon tissue lysates. Figure 6d shows the levels of WT or Nox4 - / - Immunoblotting results of TGF-β and TGFbR1 protein levels in colon tissue extracts. β-Actin was used as an internal control, and band sizes were quantified by ImageJ. Figure 6e shows the results of WT and Nox4 - / - Immunoblotting results of pSmad2 / 3, Smad2 / 3, and Smad4 protein levels in cytoplasmic and nuclear fraction extracts of mouse colon tissue. GAPDH and HDAC were used as cytoplasmic and nuclear regulatory protein controls, respectively, and band sizes were quantified by ImageJ. Figure 6f shows the results of WT or Nox4 - / - TGF-β immunofluorescence staining results of normal and inflamed colon sections of mice, and Fig. 6g shows the immunofluorescence staining results of TGF-β / CD11c / DAPI. Data are expressed as mean±SD, and significance is *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 compared to wild type (WT).
[0055] Figure 7 shows TGF-β signaling and its downstream molecules Nox4 in dextran sulfate sodium (DSS)-induced colitis. - / -It shows that it is upregulated in mice. Figure 7a is a local Fisher discriminant analysis plot for principal component analysis. The two-dimensional scores are W / DSS WT (green) and W / DSS Nox4. - / - (Red) Easily distinguishable between groups, and shared regions represent 95% confidence intervals. Figure 7b shows W / DSS WT or W / DSS Nox4 - / - Results of RNA sequencing of sorted total colon cells from mice. A heatmap of RNA sequencing data shows upregulated (purple) and downregulated (yellow) genes. Figure 7c shows the expression levels of W / DSS WT (white) and W / DSS Nox4. - / - (Red) Volcano plots identifying significantly upregulated genes in mice. Figures 7d and 7e show the expression levels of genes in WT and Nox4 - / - CIBERSORT analysis of mouse colon tissue is shown. The relative proportions of 11 different immune cell types (Fig. 7d) and 7 T cell lineage cell types (Fig. 7e) were isolated from RNA sequencing data using CIBERSORT. Figure 7f shows W / DSS WT and W / DSS Nox4. - / - A bubble plot showing significantly enriched KEGG pathways in differentially expressed genes (DEGs) across groups. Bubble color indicates the p-value and bubble size indicates the expression level. Figure 7g shows the W / DSS Nox4 - / - Heatmap of TGF-β-related gene expression in DEG. Figure 7h shows W / DSS WT or W / DSS Nox4 - / - Immunoblotting results of TGF-β and TGFbR1 protein levels from distal colon tissue extracts. β-Actin was used as an internal control, and band sizes were quantified by ImageJ. Figure 7i shows W / DSS WT and W / DSS Nox4. - / - CD4 from mouse colon tissue + RORgT for T cells +Flow cytometry plot showing the expression of . The bar graph shows WT and Nox4 - / - CD4 in the colon of mice + T cells (top right) and CD4 + RORgT + The percentage of Th17 cells (bottom right) is shown. Data are expressed as mean ± SD, and significance is *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 compared to wild type (WT).
[0056] Figure 8 shows wild type (WT) and Nox4 - / - Figure 8a shows the related physiological characteristics of the mouse colon. Figure 8b shows differentially expressed genes (DEGs) in the W / DSS WT group, and Figure 8c shows the W / DSS Nox4 group. - / - Gene ontology (GO) analysis results of upregulated gene sets among differentially expressed genes (DEGs) in the groups. Figure 8c shows the results of W / DSS WT or W / DSS Nox4 - / - The results of enzyme-linked immunosorbent assay for the level of active TGF-β in colon tissue lysates are presented. Data are expressed as mean ± SD, and significance is *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 compared to the wild type (WT).
[0057] Figure 9 shows that deletion of Nox4 impairs tissue repair in dextran sulfate sodium (DSS)-induced colitis. Figure 9a shows the experimental scheme for the recovery phase of DSS-induced murine colitis. Figure 9b shows the daily measurements of DSS-induced colitis in wild-type (WT) and Nox4 mice during the recovery phase. - / - Body weight changes in mice are shown (n = 5 per group). Figure 9c shows the changes in body weight in WT and Nox4 - / - Survival results up to 15 days after DSS-induced colitis in mice (n=5 per group). Figure 9d shows the survival rates of WT and Nox4 - / -Hematoxylin and eosin staining of colon tissue during the recovery phase after DSS-induced colitis in mice, and Figure 9e shows the quantification of colon length and disease activity index (DAI) scores. For DAI, inflammation was graded as none (0), mucosal inflammation (1), submucosal inflammation (2), and transmural inflammation (3).
[0058] Nox4 - / - To identify the underlying mechanisms contributing to the more severe inflammation and fibrosis observed in mice, we performed a bulk RNA-seq analysis. A total of 5,124 differentially expressed genes (DEGs) were compared across the four groups [untreated (W / O)Nox4 - / - vs. W / O WT, treated (W / )Nox4 - / - vs. W / WT, W / WT vs. W / O WT, and W / Nox4 - / - vs. W / ONox4 - / - ] Comparing the treated and untreated groups, 42 genes were co-upregulated and 2 genes were co-downregulated. The 42 co-regulated genes included T cell-related genes (CD3e and Tnfrsf9), fibroblast activating factors (Itg2a and Vegf), inflammasome sensor (Nlrp3), and TGF-β target genes (Ano5 and Mucl1), which were significantly upregulated compared with those in WT mice. - / - The expression levels were higher in untreated mice. Genes identified as colon cancer biomarkers, such as Tnfrsf4, Fabp7, CD79b, and Ptgs2, were expressed at higher levels compared to those in WT mice. - / - was downregulated in. These findings suggest that Nox4 deficiency inhibits TGF-β signaling.
[0059] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.
[0060] Example
[0061] [Experimental Method]
[0062] 1. Establishment of mouse and animal models
[0063] All animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee of Yonsei University, Republic of Korea (IACUI 2017-0258). Eight-week-old C57BL6 / J male mice were used. Animals were housed in a specific pathogen-free facility under a 12-h light / dark cycle and provided with PicoLab Rodent Diet 20 (LabDiet, St. Louis, MO, USA).
[0064] Nox2-null mouse (Nox2 - / - ) was established using CRISPR / Cas9 technology with exon 4 deleted (Fig. 1a). In addition, Nox4-null mice (Nox4 - / - ) was also established (Fig. 1b).
[0065] In previous studies, Nox4 - / - As mice have been reported to be susceptible to damage by the DSS regime, in this study, WT or Nox4 - / -Eight-week-old male mice were administered 2.5% DSS (MP Biochemicals, Santa Ana, CA, USA) in their drinking water for 14 days to induce fibrosing colitis. A fresh DSS solution was prepared every 2 days. For the recovery phase, mice were administered 2% (w / v) DSS in their drinking water for 5 days, followed by a 10-day recovery period with autoclaved distilled water. Control mice were provided only with autoclaved distilled water. Daily body weight changes and the Disease Activity Index (DAI) of the mice were recorded, and DSS-induced colitis activity was scored based on body weight loss (0–4), stool frequency (0–3), and rectal bleeding (0–3) (Nat Protoc 2017;12:1295–1309).
[0066] 2. Pathological analysis
[0067] Mice were sacrificed and perfused via the left ventricle with cold phosphate-buffered saline (PBS). The colon tissues obtained were then fixed overnight at 4°C with cold 4% paraformaldehyde, processed into "Swiss rolls," dehydrated, embedded in paraffin, and sectioned at 5 μm thickness. The sections were deparaffinized by washing three times in xylene for 20 min each, three times in absolute EtOH for 10 min each, twice in 90% EtOH for 10 min each, and then in 75% EtOH for 10 min. The sections were then stained with hematoxylin and eosin. The tissue slides were then dehydrated and mounted using Shandon synthetic mounting solution (Thermo Scientific).
[0068] 3. Immunohistochemical staining
[0069] During the inflammatory response in the colon, immune cell infiltration is characterized by increased levels of proinflammatory cytokines in colitis tissue. WT and Nox4 induced by DSS - / -To evaluate the immunological phenotype of the mice, immunohistochemical staining of immune cell markers was performed on colon sections. Paraffin-embedded mouse colon sections were heated at 60°C for 1 hour and then cooled to room temperature (22–25°C). Deparaffinization and tissue rehydration were performed using the same method as in [2. Pathological Analysis]. Antigen retrieval was performed at high pressure for 15 minutes using Target Retrieval Solution (Dako) and cooled to 4°C for 1 hour. The sections were treated with 3% H2O2 for 30 minutes to block endogenous peroxidase and then incubated with serum-free reagent (Dako) for 2 hours at room temperature. The sections were then treated overnight at 4°C with the primary antibodies listed in Table 1, washed with PBS, and treated with horseradish peroxidase (HRP)-labeled secondary antibodies (Dako) for 20 minutes at room temperature. Liquid DAB+ staining was performed for target detection and counterstained with Mayer's hematoxylin (Dako).
[0070] 1 stAntibodyDilutionVendorCatalogCytochrome B2451:1000Bio-RadMCA4685F4 / 801:500Cell Signaling Technology70076CD1631:1000NovusNB110-59935CD1271:1000eBioscience14-1271-82Ki-671:1000Abcamab16667TGF-beta1:100GenetexGTX21279TGFbR11:100R&D SystemMAB5871pSmad2 / 31:1000Cell Signaling Technology8828Smad2 / 31:1000Cell Signaling Technology8685Smad41:1000Cell Signaling Technology46535CD11c1:300Cell Signaling Technology97585Beta-actin1:5000Abcamab8227GAPDH1:5000Abcamab8245HDAC11:1000Abcamab280198PE anti-mouse CD41:100Biolegend100408Pacific blue anti-Foxp31:100Biolegend126409Alexa 488 anti-RORgT1:100R&D SystemIC9125G-025Cy3 affinipure Donkey anti-Mouse1:500Jackson Immunoresearch715-165-151Donkey anti-mouse IgG Alexa 4881:500InvitrogenA-21202
[0071] 4. Measurement of TGF-β activity
[0072] Expression levels of active TGF-β were measured using the TGFbR1 kinase ELISA system according to the manufacturer's instructions (Promega, Madison, WI, USA). To measure active TGFbR1, freshly isolated colon lysates were activated with 1 N HCl.
[0073] 5. RNA sequencing
[0074] Total RNA was isolated from tissues using TRIzol reagent (Invitrogen). RNA quality was assessed using an Agilent 2100 bioanalyzer with an RNA 6000 Nano Chip (Agilent Technologies, Amstelveen, the Netherlands), and RNA quantification was measured using an ND-2000 spectrophotometer (Thermo Inc., Wilmington, DE, USA).
[0075] Full-length libraries were constructed for control and sample RNA using the QuantSeq 3'mRNA-Seq Library Prep Kit (Lexogen, Inc., Austria) according to the manufacturer's instructions. Specifically, 500 ng of each RNA sample was hybridized with an oligo-dT primer containing an Illumina-compatible sequence at the 5' end, and reverse transcription was performed. After the RNA template was isolated, second-strand synthesis was initiated by a random primer containing an Illumina-compatible linker sequence at the 5' end. The double-stranded library was purified using magnetic beads to remove all reaction components, and the library was amplified to add the entire adapter sequence required for cluster generation. The library was purified from PCR components and subjected to high-throughput sequencing using the NextSeq 500 platform (Illumina, Inc., San Diego, CA, USA) using single-end 75-bp sequencing.
[0076] QuantSeq 3'mRNA-Seq reads were aligned using Bowtie2. Bowtie2 indices were generated from genome-assembled sequences or representative transcript sequences for alignment to the genome and transcriptome. Alignment files included transcript assembly and abundance estimates, as well as untreated WT (W / O WT) and untreated Nox4. - / - (W / O Nox4 - / -), DSS-treated WT (W / DSS WT), and DSS-treated Nox4 - / - (W / DSS Nox4 - / - ) was used to detect DEGs among distal colon samples. Samples were defined as DEGs using a 2-fold cutoff value and P value based on the number of unique and multiple alignments, considering the coverage of bedtools. Read count data were processed based on the Quantile Normalization method using the EdgeR package in R software with Bioconductor (R Development Core Team, 2016), and gene classification for functional investigation was based on searches of DAVID ( / david.abcc.ncifcrf.gov / ) and Medline databases ( / www.ncbi.nlm.nih.gov / ). Data mining and graphical visualization were performed using ExDEGA (Ebiogen Inc., Korea).
[0077] 6. RT-qPCR
[0078] The obtained colon tissues were treated overnight in RNAlater™ stabilization solution (Invitrogen, Thermo Fisher Scientific, Inc.) at 4°C, and total RNA was extracted using TRIzol reagent (Invitrogen, Thermo Fisher Scientific) according to the manufacturer's instructions. Contaminating genomic DNA was removed using Recombinant DNase 1 (Takara Bio Inc., Shiga, Japan), and RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific). A total of 1 μg of template RNA was reverse transcribed using the ImProm-II™ reverse transcription system (Promega). The primers used for qPCR are listed in Table 2 below.
[0079] GenesSeq. No. Sequence Accession No. Tnf Sequence No. 1F: GGTGCCTATGTCTCAGCCTCTTNM_013693 Sequence No. 2R: GCCATAGAACTGATGAGAGGGAGIl1b Sequence No. 3F: TGGACCTTCCAGGATGAGGACANM_008361 Sequence No. 4R: GTTCATCTCGGAGCCTGTAGTGCol1a1 Sequence No. 5F: CCTCAGGGTATTGCTGGACAACNM_007742 Sequence No. 6R: CAGAAGGACCTTGTTTGCCAGGCol3a1 Sequence No. 7F: GACCAAAAGGTGATGCTGGACAGNM_009930 Sequence No. 8R: CAAGACCTCGTGCTCCAGTTAGTnc Sequence No. 9F: GAGACCTGACACGGAGTATGAGNM_011607 Sequence No. 10R: CTCCAAGGTGATGCTGTTGTCTGTgfb1 SEQ ID NO: 11F: TGATACGCCTGAGTGGCTGTCTNM_011577 SEQ ID NO: 12R: CACAAGAGCAGTGAGCGCTGAATgfbr1 SEQ ID NO: 13F: TGCTCCAAACCACAGAGTAGGCNM_009370 SEQ ID NO: 14R: CCCAGAACACTAAGCCCATTGCTgfbr2 SEQ ID NO: 15F: CCTACTCTGTCTGTGGATGACCNM_009371 SEQ ID NO: 16R: GACATCCGTCTGCTTGAACGAC
[0080] 7. Western Blotting
[0081] The obtained colon tissues were treated with RIPA solution (Sigma Aldrich), and the purified proteins were loaded onto an 8–15% polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Millipore). Protein expression was detected using the primary antibodies listed in Table 1 above, and after incubation with HRP-labeled secondary antibodies, the expression levels of specific proteins were measured using Signal West Femto Maximum Sensitivity Substrate (Thermo Scientific) together with a LAS chemiluminescence imaging system (Amersham).
[0082] 8. Flow Cytometry
[0083] CD4+ and Foxp3+ Tregs or RORgT in the colon + To detect Th17 cells, single cells were isolated from tissues. Cells were Fc blocked by treating with fluorescence-activated cell sorting (FACS) buffer (0.5% fetal bovine serum, 10 mM EDTA, and 0.05% NaN3 in PBS) at 4°C for 30 minutes. Cells were then treated with phycoerythrin-conjugated anti-mouse CD4 (Biolegend), Pacific Blue-conjugated anti-mouse Foxp3 (Biolegend), or Alexa 488-conjugated anti-mouse RORgT (R&D Systems) for 1 hour at 4°C. After washing with FACS buffer, cells were gated and sorted on CD4+ and Foxp3+ cell fractions for quantification on a FACS Aria II cell sorter (BD Biosciences).
[0084] 9. Statistical processing
[0085] Data are expressed as mean ± SD. Significant differences were assessed by one-way analysis using Student's t-test, Mann-Whitney U test, or Prism9 (GraphPad Software, USA), and P < 0.05 was considered statistically significant.
[0086] [Experimental Results]
[0087] 1. Nox4 protects tissues from DSS-induced colitis.
[0088] To investigate the role of Nox4 in the development of fibrosis in DSS-induced colitis, we confirmed Nox4 expression in mouse tissues. Immunohistochemistry was performed on normal colon and DSS-treated inflamed colon tissues. Nox4 was detected in the interstitial region of normal colon (Fig. 1c, upper left), whereas the level of Nox4 transcript was significantly increased in the mucosal and submucosal regions of colitis model administered with 2.5% DSS (Fig. 1c, lower left). Loss of Nox4 increased ROS production in both control (Fig. 1e) and DSS-induced colitis model (Fig. 1f) mice, suggesting that Nox4 elevation may be associated with disease progression. After inducing the inflammatory phase of colitis by DSS treatment (W / DSS) (Fig. 2a), Nox4 - / - Mice showed aggravated inflammation with rapid weight loss of approximately 20-30% (Fig. 2b) and decreased survival (Fig. 2c), and compared with wild-type mice (WT), the colon was shorter and more severely inflamed areas in the distal colon, including infiltration of inflammatory cells and loss of crypts (Fig. 2e, f). W / DSS Nox4 - / - Mice showed higher disease activity index (DAI) scores from day 1 to day 14 than the W / DSS WT group (Fig. 2g). W / DSS Nox4 - / -The colons of W / DSS mice showed 1.5-fold higher H2O2 / ROS production than those found in the colons of WT mice (Fig. 1g). These results indicate that Nox4 plays a protective role against DSS-induced colitis by suppressing ROS production. Nox2 was expressed primarily in immune cells (Fig. 1c, upper right). W / DSS Nox2 - / - Mice did not develop severe colitis, and body weight changes were less reduced than those found in W / DSS WT mice (Fig. 2b). In addition, W / DSS Nox2 - / - Mice showed high survival rates (Fig. 2c) and no significant changes in colon length compared with WT mice (Fig. 2d). DSS-treated W / DSS Nox2 - / - Histological examination of the mouse colon revealed elongated crypts, immune cell infiltration, and loss of goblet cells (Fig. 1d), indicating colonic damage. However, W / DSS WT and W / DSS Nox4 - / - The damage scores were significantly lower compared to mice (Fig. 2f-g). Consistent with these results, W / DSS Nox2 - / - Mice did not develop fibrotic areas in the colon after DSS administration (Fig. 1e). In conclusion, Nox2 deficiency caused mild inflammation in DSS-induced colitis, whereas W / DSS Nox4 deficiency showed severe colon damage in DSS-induced colitis. Therefore, Nox4 - / - The inflammatory properties of the mice were further investigated.
[0089] 2. Nox4 deficiency increases intestinal fibrosis in DSS-induced colitis.
[0090] Immunohistochemical staining of colon tissue for Nox4 - / - F4 / 80 in colon tissue compared to WT colon + While M1 macrophages increased (Fig. 3a, top), CD163 +M2 macrophages were significantly reduced (Fig. 3b, middle). CD127 + Lymphocytes express Nox4 in DSS-induced colitis - / - In mice, the expression of Ki-67 was also increased (Fig. 3a, bottom). Ki-67 immunostaining was also shown in DSS-induced colitis Nox4 - / - Compared with WT mice, DSS-induced colitis showed a significant increase in colons (Fig. 3b). This result indicates that Nox4 - / - This suggests that mice do not exhibit a typical repair response to colitis-induced damage. Sirius red staining showed increased intestinal fibrosis (Fig. 3c, top), consistent with increased expression of common fibrosis markers such as Col1a1 and Col3a1 (Fig. 3e), as detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Levels of Tenascin-C, a specific diagnostic marker of collagenous colitis, were significantly increased in colitis-induced Nox4 at both protein (Fig. 3c, bottom) and mRNA (Fig. 3e) levels compared to colitis. - / - In the colon, the mRNA levels of inflammatory cytokines tumor necrosis factor (Tnf) and interleukin-1beta (Il1β) were significantly increased. In addition, the mRNA levels of Nox4, which induces colitis, were also increased. - / - In mice, colitis was significantly increased at the same time point compared to WT mice (Fig. 3d). Moreover, in untreated conditions (without DSS), Nox4 - / - Mouse is F4 / 80 + Macrophages and Ki-67 + showed an increase in proliferative cells (Fig. 4a). The mRNA levels of fibrosis-related markers and inflammatory cytokines Tnf and Il1β were also increased by Nox4 - / - increased in mice (Fig. 3d, Fig. 3e). In addition, untreated Nox4 - / - The colons of mice had larger areas of fibrosis as detected by Tenascin-C immunostaining compared to the colons of WT mice (Fig. 4b). These results suggest that Nox4 - / -The more severe inflammatory response to DSS induction in mice suggests that Nox4 deficiency is associated with activation of intestinal inflammation and fibrosis.
[0091] 3. Differential gene expression under Nox4 deficiency in distal colon tissue.
[0092] Nox4 - / - To identify the underlying mechanisms contributing to the more severe inflammation and fibrosis observed in mice, we performed bulk RNA-seq analysis (Fig. 5a). A total of 5,124 differentially expressed genes (DEGs) were compared across the four groups [untreated (W / O)Nox4 - / - vs. W / O WT, treated (W / )Nox4 - / - vs. W / WT, W / WT vs. W / O WT, and W / Nox4 - / - vs. W / ONox4 - / - ] Comparing the treated and untreated groups, 42 genes were co-upregulated and 2 genes were co-downregulated (Fig. 5b). The 42 co-regulated genes included T cell-related genes (CD3e and Tnfrsf9), fibroblast activating factors (Itg2a and Vegf), inflammasome sensor (Nlrp3), and TGF-β target genes (Ano5 and Mucl1), which were significantly upregulated compared with those in WT mice. - / - The expression levels were higher in untreated mice. Genes identified as colon cancer biomarkers, such as Tnfrsf4, Fabp7, CD79b, and Ptgs2, were expressed at higher levels compared to those in WT mice. - / - was downregulated in (Fig. 5c). These findings suggest that Nox4 deficiency inhibits TGF-β signaling. Nox4 - / -To evaluate the biological functions of genes with increased expression in , functional enrichment analysis of DEGs, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, was performed using databases for annotation, visualization, and integrated search. GO analysis was performed on Nox4 - / - Most of the DEGs in the mice were enriched for collagen-related responses, TGF-β stimulation, and cell repair processes compared to WT mice (Fig. 5d). KEGG analysis also revealed that Nox4 was associated with type 2 immune responses, collagen processing, and inflammatory responses (immune system processes, responses to lipopolysaccharides, and redox processes). - / - showed high expression of DEGs (Fig. 5e). Further investigation using cell type identification using CIBERSORT (Cell-type Identification by Estimating Relative Subsets of RNA Transcripts) with 11 immune signature gene sets revealed that Nox4 - / - The colon showed a predominant increase in regulatory T cells (Treg) and a decrease in plasma cells compared to WT (Fig. 5f and 5g). Flow cytometric analysis of colon tissues revealed that loss of Nox4 resulted in an increase in CD4 + Foxp3 + We confirmed that Tregs increased fourfold (Fig. 5h).
[0093] 4. Nox4 deficiency activates the TGF-β signaling pathway.
[0094] Gene set enrichment analysis revealed that Nox4 was significantly enriched compared to WT DEGs. - / -Upregulation of a set of TGF-β signaling-stimulated genes was confirmed in the DEG (Fig. 5i). Therefore, further focus was placed on the role of Nox4 in canonical TGF-β signaling in the colon. Activation of canonical TGF-β signaling involves the binding of TGF-β to TGFβR2, which in turn phosphorylates TGFβR1, leading to phosphorylation of Smad2 / 3 (pSmad2 / 3) and Smad4, ultimately promoting the nuclear translocation of pSmad2 / 3 and Smad4 (Fig. 6a). Our results showed that Nox4 was significantly more abundant in the untreated colon than in the WT colon. - / - We observed higher mRNA expression of Tgfbr1 in colon tissue, whereas there was no difference in mRNA levels of Tgfbr2 and Tgfb1 between the two groups (Fig. 6b). Enzyme-linked immunosorbent assay (ELISA) revealed higher mRNA expression of Nox4 compared to WT colon. - / - Increased levels of the active form of TGF-β were observed in the colon (Fig. 6c). Consistently, Western blot analysis showed that Nox4 was upregulated compared to the WT group. - / - Increased TGF-β and TGFβR1 protein levels were observed in colon tissue lysates (Fig. 6d). To verify phosphorylation of Smad2 / 3, total Smad2 / 3, and Smad4 by TGFβR1, cytoplasmic-nuclear fractions of each colon tissue lysate were evaluated, which revealed that Nox4 - / - In the group, increased translocation of cytoplasmic pSmad2 / 3 and Smad4 to the nucleus was observed compared to the WT group (Fig. 6e). TGFβ + Cells express Nox4 - / - It was expressed in the lamina propria rather than the epithelium of the colon, and TGF-β + The number of cells was significantly higher (Fig. 6f). Immunofluorescence staining of the colon showed TGF-b + CD11c on cells +We further demonstrated co-expression of dendritic cells (Fig. 6g). Overall, these results strongly suggest that Nox4 deficiency induces TGF-β activation in the colon, leading to fibrotic gene expression and Tregs.
[0095] 5. Nox4 deficiency worsens colitis by promoting intestinal inflammation through inducing the TGF-β pathway.
[0096] Based on the above results, to determine whether TGF-β signaling continuously affects intestinal inflammation during DSS-induced colitis, WT and Nox4 treated with DSS - / - We further analyzed bulk RNA-seq data from mice. Principal component analysis revealed that W / DSS Nox4 - / - The transcriptome was clearly distinct from that of W / DSS WT mice (Fig. 7a). Compared with W / DSS WT mice, W / DSS Nox4 - / - In mice, 247 upregulated genes and 179 downregulated genes were identified, resulting in a total of 427 DEGs that were significantly different between the two groups (P < 0.05; fold change, >2) (Fig. 7b). In particular, W / DSS Nox4 - / - In mice, significant expression levels of TGF-β-related genes, such as Asap3 and Tgfbr1, which are positive regulators of the TGF-β pathway, were observed. Inflammatory Th17 cell differentiation genes, such as Plekha and Batf, and fibrosis-related genes, such as Acta1 and Myo6, which promote collagen synthesis, were also increased. In contrast, ulcerative colitis (UC)-related genes, such as Chic1, Ido1, and Reg3g, and immune infiltration-related genes, such as Tmco3, Orai2, and Saa2, were upregulated in W / DSS WT mice (Fig. 7c). CIBERSORT was used to determine the expression levels of Nox4 in W / DSS compared to W / DSS WT colons. - / -We confirmed that the proportion of Th17 cells in the colon was significantly increased (Fig. 7d, Fig. 7e). W / DSS WT or W / DSS Nox4 - / - GO analysis of DEGs showed enrichment of up-regulated W / DSS WT DEGs in tissue repair mechanisms such as proliferation, wound healing, and defense responses in terms of cellular components related to colitis-mediated functions such as innate immune response, biological stimuli, and cytokines. Similarly, up-regulated W / DSS WT DEGs were enriched in biological processes of endoplasmic reticulum stress and tissue repair mechanisms associated with intestinal inflammation, such as innate immune response and cytokine production. DEGs were enriched in molecular function GO terms included in the inflammatory bowel disease (IBD) pathophysiology-related gene set, such as calcium ion binding, peptidase activity, and signal transduction-related functions (Fig. 8a). However, W / DSS Nox4 - / - DEGs showed different functional patterns. In terms of GO cellular components, DEGs were enriched in tissue damage gene sets, such as apoptosis, inflammation, and injury. Among them, the most enriched gene set was identified as a tissue fibrosis-related gene set, such as catalytic complex, cytoskeletal part, and ribonucleoprotein complex. In terms of molecular function components, highly enriched DEGs were identified as a UC-related oncogene set, such as protein binding, protein kinase activity, histone acetyltransferase activity, and oxidoreductase activity (Fig. 8b). KEGG pathway analysis showed that DEGs in W / DSS WT were enriched in the Toll-like receptor pathway, JAK-STAT pathway, and mitogen-activated protein kinase pathway, whereas DEGs in W / DSS Nox4 - / - The DEGs were enriched in gene sets of the TGF-β pathway, and the T cell receptor and rapamycin pathways (Fig. 7f). In addition, the heatmap showed that W / DSS Nox4 - / -It was confirmed that the expression level of TGF-β target genes in the DEG of the group was significantly increased compared to the DEG of the W / DSS group (Fig. 7g).
[0097] These findings suggest that TGF-β signaling and its associated fibrosis and T cell signaling are persistently increased in the colons of Nox4-deficient mice, contributing to the maintenance of more severe inflammation. In line with these results from RNA-seq analysis, Western blotting revealed that W / DSS Nox4 was significantly increased compared to W / DSS WT colon lysates. - / - Elevated TGF-β and TGFbR1 protein levels were observed in colon lysates (Fig. 7h). Analysis by ELISA also showed that active TGF-β levels were higher in W / DSS Nox4 than in W / DSS WT colons. - / - A two-fold increase was confirmed in the colon (Fig. 8c). Flow cytometry analysis results showed an increase in CD4+ T cells in the W / DSS WT colon. However, W / DSS Nox4 - / - CD4 in the colon + About 59% of the cells expressed RORγT, a marker of Th17 cells. + , which was increased compared to the W / DSS WT colon (Fig. 7i). This finding suggests that Nox4 - / - This suggests an association between DSS-induced inflammation and an increase in Th17 lineage cells in the colon.
[0098] 6. Nox4 is required for intestinal recovery from DSS-induced acute colitis.
[0099] Finally, we investigated whether Nox4 is required for recovery from intestinal inflammation (Fig. 9a). The body weight of W / DSS WT mice began to improve on day 9 (2 days after DSS treatment), whereas that of W / DSS Nox4 - / - Body weight of mice continued to decrease during the recovery phase after 2.5% DSS administration, and a more rapid weight loss was observed. W / DSS Nox4 experienced a weight loss of more than 30%. - / -Mice did not survive (Fig. 9b). Therefore, W / DSS Nox4 - / - Overall survival was significantly reduced in mice treated with W / DSS Nox4 (Fig. 9c). - / - Because none of the mice survived to the end point, all colon tissues were obtained on day 10 for histological analysis. In the recovery phase, W / DSS WT mice showed epithelial repair, mucosal healing, and only moderate inflammation on day 10, whereas W / DSS Nox4 - / - Mice still showed crypt atrophy, severe immune cell infiltration, and epithelial histiocyte formation (Fig. 9d). The mean percentage of colon length, an indicator of colitis severity, was significantly higher in W / DSS Nox4 than in W / DSS WT colons. - / - was significantly lower in the colon (Fig. 9e, left). Moreover, W / DSS Nox4 - / - The number of goblet cells detected in colonic sections was reduced by more than twofold (Fig. 9e, right). Collectively, these results indicate that loss of Nox4 impairs the overall recovery process after DSS-induced colitis, leading to chronic colitis and affecting overall survival.
[0100] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0101] In this study, the researchers demonstrated that genetic deletion of Nox4 leads to the progression of more severe fibrosing colitis and subsequent failure to recover. Loss of Nox4 increased oxidative stress in colonic tissue, which subsequently permanently activated canonical TGF-β signaling. Furthermore, it affected the differentiation and proliferation of TGF-β-mediated T cell lineages (Treg and Th17 cells) and the progression of fibrosis in colitis. Therefore, the present invention is expected to be of significant use in predicting and suppressing the progression of fibrosis in inflammatory bowel disease.
[0102] Sequence number 1: Tnf primer_F
[0103] GGTGCCTATGTCTCAGCCTCTT
[0104] Sequence number 2: Tnf primer_R
[0105] GCCATAGAACTGATGAGAGGGAG
[0106] Sequence number 3: Il1b primer_F
[0107] TGGACCTTCCAGGATGAGGACA
[0108] Sequence number 4: Il1b primer_R
[0109] GTTCATCTCGGAGCCTGTAGTG
[0110] Sequence number 5: Col1a1 primer_F
[0111] CCTCAGGGTATTGCTGGACAAC
[0112] Sequence number 6: Col1a1 primer_R
[0113] CAGAAGGACCTTGTTTGCCAGG
[0114] Sequence number 7: Col3a1 primer_F
[0115] GACCAAAAGGTGATGCTGGACAG
[0116] Sequence number 8: Col3a1 primer_R
[0117] CAAGACCTCGTGCTCCAGTTAG
[0118] Sequence number 9: Tnc primer_F
[0119] GAGACCTGACACGGAGTATGAG
[0120] Sequence number 10: Tnc primer_R
[0121] CTCCAAGGTGATGCTGTTGTCTG
[0122] Sequence number 11: Tgfb1 primer_F
[0123] TGATACGCCTGAGTGGCTGTCT
[0124] Sequence number 12: Tgfb1 primer_R
[0125] CACAAGAGCAGTGAGCGCTGAA
[0126] SEQ ID NO: 13: Tgfbr1 primer_F
[0127] TGCTCCAAACCACAGAGTAGGC
[0128] SEQ ID NO: 14: Tgfbr1 primer_R
[0129] CCCAGAACACTAAGCCCATTGC
[0130] SEQ ID NO: 15: Tgfbr2 primer_F
[0131] CCTACTCTGTCTGTGGATGACC
[0132] SEQ ID NO: 16: Tgfbr2 primer_R
[0133] GACATCCGTCTGCTTGAACGAC
Claims
1. Contains a preparation capable of measuring the expression level of Nox4 (NADPH Oxidase 4) protein or a gene encoding it, A composition for predicting the progression of fibrosis in colitis, further comprising an agent capable of measuring the expression level of any one or more proteins selected from the group consisting of CD3e (Cluster of Differentiation 3 epsilon), Mucl1 (Mucin Like 1), Vegf (vascular endothelial growth factor), Ano5 (Anoctamin 5), Tnfrsf9 (TNF Receptor Superfamily Member 9), Itg2a (Integrin α2), Nlrp3 (NLR family pyrin domain containing 3), Tnfrsf4 (TNF Receptor Superfamily Member 4), Fabp7 (Fatty Acid Binding Protein 7), CD79b (Cluster of Differentiation 79B), Ptgs2 (Prostaglandin-endoperoxide synthase 2), and Caprin2 (Caprin Family Member 2), or a gene encoding the same.
2. In paragraph 1, A composition wherein the above colitis is ulcerative colitis.
3. In paragraph 1, A composition comprising a preparation for measuring the expression level of the protein, wherein the preparation comprises at least one selected from the group consisting of an antibody, an oligopeptide, a ligand, a peptide nucleic acid (PNA), and an aptamer that specifically binds to the protein.
4. In paragraph 1, A composition comprising a preparation for measuring the expression level of the gene, wherein the preparation comprises at least one selected from the group consisting of a primer, a probe, and an antisense nucleotide that specifically bind to the gene.
5. A kit for predicting the progression of fibrosis in colitis, comprising the composition of paragraph 1.
6. In paragraph 5, The above kit is a kit that is an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or an MRM (Multiple reaction monitoring) kit.
7. In biological samples isolated from colitis subjects, (a) a step of confirming an increase in the expression of Nox4 (NADPH Oxidase 4) protein or a gene encoding the same; and, (b) A method for predicting whether fibrosis progresses in colitis, comprising a step of confirming an increase or decrease in the expression of at least one protein selected from the group consisting of CD3e (Cluster of Differentiation 3 epsilon), Mucl1 (Mucin Like 1), Vegf (vascular endothelial growth factor), Ano5 (Anoctamin 5), Tnfrsf9 (TNF Receptor Superfamily Member 9), Itg2a (Integrin α2), Nlrp3 (NLR family pyrin domain containing 3), Tnfrsf4 (TNF Receptor Superfamily Member 4), Fabp7 (Fatty Acid Binding Protein 7), CD79b (Cluster of Differentiation 79B), Ptgs2 (Prostaglandin-endoperoxide synthase 2), and Caprin2 (Caprin Family Member 2), or a gene encoding the same.
8. In paragraph 7, A method wherein the above colitis is ulcerative colitis.
9. In paragraph 7, The biological samples include tissue, cells, cell extracts, whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid. A method, wherein the fluid is at least one selected from the group consisting of joint aspirate, organ secretions, and cerebrospinal fluid.
10. In paragraph 7, A method for predicting that fibrosis is likely to progress in colitis when the expression of any one or more proteins selected from the group consisting of CD3e, Mucl1, Vegf, Ano5, Tnfrsf9, Itg2a, and Nlrp3, or a gene encoding the same, is increased.
11. In paragraph 7, A method for predicting that fibrosis is likely to progress in colitis when the expression of any one or more proteins selected from the group consisting of Tnfrsf4, Fabp47, CD79b, Ptgs2, and Caprin2, or a gene encoding the same, is reduced.
12. In paragraph 7, A method wherein the expression increase or decrease of the above protein or gene is at least twice that of a normal control group.
13. In paragraph 7, A method wherein the increase in expression of the Nox4 (NADPH Oxidase 4) protein or the gene encoding it is regulated by TGF-β (Transforming growth factor-beta).
14. In paragraph 7, The above method, (c) F4 / 80 + M1 macrophages, CD127 + Lymphocytes, regulatory T cells, or RORγT + A method further comprising a step of confirming an increase in Th17 cells (T helper 17 cells).
15. In paragraph 7, The above method, (c) CD163 + A method further comprising: a step of confirming a decrease in M2 macrophages.
Citation Information
Patent Citations
Compositions and methods for diagnosing and treating fibrotic disorders
US20120141461A1
Methods and uses of inflammatory bowel disease biomarkers
WO2019018571A1
